·PIB

Union Minister of Commerce and Industry Shri Piyush Goyal Calls on MedTech Startups to Go Global, Leverage Trade Pacts Covering 70% of World GDP

In this note
  1. At a Glance
  2. Why in the News
  3. Background & Evolution
  4. Core Static Facts
  5. Multi-Dimensional Analysis
  6. Recent Developments (12–18 months)
  7. Prelims Hooks
  8. Mains Relevance
  9. Related Topics to Study Next
  10. Common Errors / Trap Areas

1. At a Glance

  • Union Minister of Commerce & Industry Piyush Goyal urged Indian MedTech startups to scale globally by leveraging India's 9 FTAs covering 38 countries and ~70% of world GDP at mostly zero duty [1][2].
  • Announcement bundles trade-policy (FTAs), industrial-R&D (NIPER expansion, new NID), and startup-ecosystem (80% IP-fee rebate) levers — a one-stop convergence relevant to GS-II (Govt schemes) and GS-III (Economy, S&T, IPR).

2. Why in the News

  • On 12 Feb 2026, Goyal addressed the Pfizer INDovation Startup Showcase Programme, New Delhi, exhorting MedTech startups to "Go Global" [1].
  • Coincides with cascade of new FTAs: India–UK CETA (Jul 2025), India–Oman CEPA (Dec 2025), India–New Zealand FTA (22 Dec 2025), India–EU FTA (27 Jan 2026), and India–US interim framework (7 Feb 2026) [2].

3. Background & Evolution

  • NIPER: First established at Mohali (1998) under the NIPER Act, 1998; declared Institute of National Importance; admin ministry — Dept. of Pharmaceuticals, Ministry of Chemicals & Fertilizers [3].
  • Startup India: Launched 16 Jan 2016; 80% rebate on patent filing fees and 50% on trademark fees are flagship IPR sops [1].
  • FTA trajectory: India–Mauritius CECPA (2021) → India–UAE CEPA (May 2022) → India–Australia ECTA (Dec 2022) → India–EFTA TEPA (signed 10 Mar 2024, in-force 1 Oct 2025) → UK/Oman/NZ/EU/US in 2025–26 [2].

4. Core Static Facts

  • Programme platform: Pfizer INDovation Startup Showcase, New Delhi, 12 Feb 2026 [1].
  • Speaker: Shri Piyush Goyal, Union Minister of Commerce & Industry [1].
  • FTA count: 9 FTAs in ~3 years; 38 countries; ~70% of global GDP; "mostly zero duty" market access [1][2].
  • NIPER expansion: 3 new NIPERs + upgradation of 7 existing NIPERs; existing NIPERs at Mohali, Ahmedabad/Gandhinagar, Hyderabad, Kolkata, Guwahati, Hajipur, Raebareli [1][3].
  • New NID (National Institute of Design) to be set up in East India [1].
  • IPR sop: 80% rebate on IP filing fees for recognized startups; 24x7 Startup India team support [1].
  • Parent Ministry: Ministry of Commerce & Industry — DPIIT runs Startup India [1].

5. Multi-Dimensional Analysis

Economic

  • FTAs unlock duty-free access for India's $50+ bn pharma export base and nascent MedTech segment (currently ~75% import-dependent) [1][2].
  • Aligns with PLI for Medical Devices (DoP) and Promotion of Medical Device Parks scheme.

Scientific / Technological

  • NIPER upgradation feeds R&D pipeline for biosimilars, medical devices, phytopharmaceuticals (CoEs at Ahmedabad, Hyderabad, Guwahati, Mohali) [3].
  • Biopharma SHAKTI envisages institutional network of 3 new + 7 upgraded NIPERs [3].

Geopolitical / Strategic

  • FTA web with UAE, Australia, EFTA, UK, Oman, NZ, EU, US reorients India away from RCEP (which India exited in Nov 2019) toward bilateral/plurilateral deals with developed markets [2].

Administrative / Governance

  • Convergence of three ministries — Commerce (FTAs, Startup India), Chemicals & Fertilizers (NIPER), Textiles (NID) — under one ministerial portfolio held by Goyal.

Legal / IPR

  • IP-fee rebate operates under Startup India Action Plan, 2016 and SIPP (Scheme for Facilitating Startups Intellectual Property Protection) [1].

6. Recent Developments (12–18 months)

  • 10 Mar 2024: India–EFTA TEPA signed; 1 Oct 2025: entered into force [2].
  • Jul 2025: India–UK CETA signed [2].
  • Dec 2025: India–Oman CEPA; India–New Zealand FTA (22 Dec 2025) [2].
  • 27 Jan 2026: India–EU FTA concluded [2].
  • 7 Feb 2026: India–US interim trade framework delivered [2].
  • 12 Feb 2026: Goyal's MedTech address at Pfizer INDovation [1].

7. Prelims Hooks

  • India has signed 9 FTAs covering 38 countries (~70% of global GDP) as of Feb 2026 [1][2].
  • EFTA TEPA in-force date: 1 October 2025; EFTA = Switzerland, Norway, Iceland, Liechtenstein [2].
  • NIPER Act, 1998 — Institutes of National Importance under Dept. of Pharmaceuticals, NOT Ministry of Education [3].
  • Existing NIPERs = 7 (Mohali, Ahmedabad, Hyderabad, Kolkata, Guwahati, Hajipur, Raebareli) [3].
  • Startup India launched 16 Jan 2026 — admin by DPIIT under Commerce Ministry [1].
  • 80% rebate on patent fees for recognised startups (SIPP scheme) [1].
  • India–UAE CEPA = India's first CEPA with an Arab nation, signed Feb 2022, in-force May 2022 [2].
  • India–Australia ECTA in force from 29 Dec 2022 [2].
  • India–EU FTA announced 27 January 2026 [2].
  • Pfizer INDovation = pharma industry–startup showcase; venue New Delhi, 12 Feb 2026 [1].
  • New NID announced for East India — NIDs are under Ministry of Commerce & Industry (DPIIT), not Culture/Education.
  • India exited RCEP in November 2019 — context for pivot to bilateral FTAs.

8. Mains Relevance

  • GS-II: Government policies & interventions — Startup India, IP regime.
  • GS-III: Indian Economy (FTAs, exports); Science & Tech (pharma/MedTech R&D); IPR.
  • Possible stems: 1. "India's recent FTAs mark a strategic pivot toward bilateral engagement with developed economies. Discuss in the context of the MedTech and pharma sectors." (GS-III) 2. "Evaluate the role of NIPERs and the Startup India IPR framework in building India as a global MedTech hub." (GS-III) 3. "Examine how trade agreements covering 70% of world GDP can be leveraged for Atmanirbhar Bharat in healthcare." (GS-III)

9. Related Topics to Study Next

  • PLI Scheme for Medical Devices & Bulk Drugs — supply-side complement.
  • India–EU FTA / India–UK CETA — flagship 2025–26 deals.
  • Patents (Amendment) Rules 2024 — IPR ecosystem.
  • Jan Aushadhi & PMBJP — domestic affordability angle.
  • DCGI & CDSCO — MedTech regulatory architecture.
  • National Medical Devices Policy 2023 — sectoral roadmap.
  • RCEP exit (2019) — comparative trade strategy.
  • Startup India Seed Fund Scheme (SISFS) — financing layer.

10. Common Errors / Trap Areas

  • NIPER ≠ NIPFP. NIPER (Pharma, Dept. of Pharmaceuticals); NIPFP (Public Finance, Finance Ministry).
  • NID is under DPIIT (Commerce Ministry), not Ministry of Education or Culture.
  • EFTA ≠ EU. EFTA = Switzerland, Norway, Iceland, Liechtenstein; India–EU FTA is separate (Jan 2026).
  • "9 FTAs" is the count touted in Feb 2026 — older sources may say 13 (counts include older CECAs with Singapore, Japan, Korea, ASEAN).
  • Startup IP rebate is 80% on patents and 50% on trademarks — don't conflate.
  • India–UAE deal is a CEPA, India–Australia is ECTA (interim), India–UK is CETA — terminology distinct.

Sources

  1. 1Piyush Goyal Calls on MedTech Startups to Go Global …pib.gov.in · tier 1
  2. 2FTAs Opening New Opportunities for Pharma, Healthcare and MedTech Sectorspib.gov.in · tier 1
  3. 3Transforming India into a Global Biopharma Hub / NIPER CoEs — andpib.gov.in · tier 1

Also on 12 February

All 12 February articles →